In Brief: Chiron Vision/Iolab consolidation
This article was originally published in The Gray Sheet
Chiron Vision/Iolab consolidation: Combined company should be profitable by "third or fourth quarter this year" and should be "a substantial contributor to profitability on a margin basis by 1996" in the wake of a recent layoff of 200 employees and the closing of 5 plants, Chiron VP-corporate communications Larry Kurtz tells analysts May 17 at the Alex. Brown & Sons healthcare seminar. Chiron indicated its plans for the cuts when it acquired Iolab from Johnson & Johnson for $95 mil. in March ("The Gray Sheet" March 13, p. 15)...
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.